Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A digenic human immunodeficiency characterized by IFNAR1 and IFNGR2 mutations
Rodrigo Hoyos-Bachiloglu, … , Mofareh AlZahrani, Raif S. Geha
Rodrigo Hoyos-Bachiloglu, … , Mofareh AlZahrani, Raif S. Geha
Published November 6, 2017
Citation Information: J Clin Invest. 2017;127(12):4415-4420. https://doi.org/10.1172/JCI93486.
View: Text | PDF
Concise Communication Immunology Virology

A digenic human immunodeficiency characterized by IFNAR1 and IFNGR2 mutations

  • Text
  • PDF
Abstract

Primary immunodeficiencies are often monogenic disorders characterized by vulnerability to specific infectious pathogens. Here, we performed whole-exome sequencing of a patient with disseminated Mycobacterium abscessus, Streptococcus viridians bacteremia, and cytomegalovirus (CMV) viremia and identified mutations in 2 genes that regulate distinct IFN pathways. The patient had a homozygous frameshift deletion in IFNGR2, which encodes the signal transducing chain of the IFN-γ receptor, that resulted in minimal protein expression and abolished downstream signaling. The patient also harbored a homozygous deletion in IFNAR1 (IFNAR1*557Gluext*46), which encodes the IFN-α receptor signaling subunit. The IFNAR1*557Gluext*46 resulted in replacement of the stop codon with 46 additional codons at the C-terminus. The level of IFNAR1*557Gluext*46 mutant protein expressed in patient fibroblasts was comparable to levels of WT IFNAR1 in control fibroblasts. IFN-α–induced signaling was impaired in the patient fibroblasts, as evidenced by decreased STAT1/STAT2 phosphorylation, nuclear translocation of STAT1, and expression of IFN-α–stimulated genes critical for CMV immunity. Pretreatment with IFN-α failed to suppress CMV protein expression in patient fibroblasts, whereas expression of WT IFNAR1 restored IFN-α–mediated suppression of CMV. This study identifies a human IFNAR1 mutation and describes a digenic immunodeficiency specific to type I and type II IFNs.

Authors

Rodrigo Hoyos-Bachiloglu, Janet Chou, Catherine N. Sodroski, Abdallah Beano, Wayne Bainter, Magdalena Angelova, Eman Al Idrissi, Murad K. Habazi, Hamza Ali Alghamdi, Fahd Almanjomi, Mohamed Al Shehri, Nagi Elsidig, Morsi Alaa Eldin, David M. Knipe, Mofareh AlZahrani, Raif S. Geha

×

Figure 1

IFNGR2C266fs has minimal protein expression and abrogates downstream signaling.

Options: View larger image (or click on image) Download as PowerPoint
IFNGR2C266fs has minimal protein expression and abrogates downstream sig...
(A) Pedigree of the proband’s family. No one in the extended family has recurrent infections. (B) Schematic of wild-type (WT) and the mutant (IFNGR2C266fs) IFNGR2. EC, extracellular domain; TM, transmembrane domain; IC, intracellular domain. (C) Quantitative PCR of IFNGR2 mRNA from control and proband (Pt) fibroblasts, normalized to GAPDH as a housekeeping gene and expressed relative to the control. (D) Flow cytometric analysis of the wild-type (WT IFNGR2) and mutant (IFNGR2C266fs) protein expression on CD14+ cells from a control and the proband, respectively. (E) Decay curves of WT and mutant IFNGR2 transfected into 293T cells, treated with the protein inhibitor cycloheximide (CHX) with or without the proteasome inhibitor MG132. **P < 0.01, ***P < 0.001, 2-way ANOVA. Results are pooled from 3 experiments. (F) Immunoblot of STAT1 phosphorylation after IFN-γ stimulation of fibroblasts from the proband and a control. (G) Flow cytometric analysis of HLA-DR expression on patient or control fibroblasts stimulated with IFN-γ. All data are representative of 3 independent experiments using 2 controls.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts